# Development of a new TLR4 agonist for the treatment of Allergic Rhinitis

> **NIH NIH N44** · INIMMUNE CORPORATION · 2021 · $1,836,453

## Abstract

The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis.  Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.

## Key facts

- **NIH application ID:** 10488952
- **Project number:** 75N93021C00044-0-9999-1
- **Recipient organization:** INIMMUNE CORPORATION
- **Principal Investigator:** JUHIENAH KHALAF
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,836,453
- **Award type:** —
- **Project period:** 2021-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10488952

## Citation

> US National Institutes of Health, RePORTER application 10488952, Development of a new TLR4 agonist for the treatment of Allergic Rhinitis (75N93021C00044-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10488952. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*